From discoveries to inventions

IsomAb is developing isoform specific antibodies to treat patients with diseases that currently have limited or no treatment options. Its bioinformatics and knowledge-based platform approach has identified the therapeutic antibody ISM-001 as a development candidate for peripheral arterial disease (PAD). By progressing this through clinical trials, it has the potential to significantly improve the wellbeing of those affected by PAD which causes risk factors such as type 2 diabetes, obesity and high blood pressure.

Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.

Native Labs is transforming bioprocesses for cellular innovations with its manufacturing technology. By applying its intelligent operating system, Native Labs harnesses state-of-the-art, neural network-based models to accelerate predictions, enable precise control and release products confidently through real-time quality verification. This approach offers a cost-effective, time-efficient manufacturing alternative for bioprocesses, from regenerative medicine to cultivated protein.